Clinical trial NCT05006716 of Beigene’s BGB-16673, a Bruton Tyrosine Kinase Targeted Protein Degrader, is recruiting patients in Calgary, Edmonton, Québec, Vancouver, and Toronto. Official title of the study: A Phase 1/2, Open-Label, Dose Escalation and Expansion Study of the Bruton Tyrosine Kinases Targeted Protein Degrader BGB-16673 in Patients with B-cell Malignancies. For more information, see the trial’s description on the NIH website.